Back-extrapolates a measured post-distribution Gentamicin concentration to a selected peak reference time. This guide explains the pharmacokinetic source, assumptions, safe unit handling, interpretation, monitoring and limitations.
Overview
Back-extrapolates a measured post-distribution Gentamicin concentration to a selected peak reference time.
Clinical Significance
This is a model-based Gentamicin concentration at the selected post-infusion reference time. Compare only with a target defined at the same reference time.
When to Use
- Use when the required concentration, timing and dosing information are reliable and the stated pharmacokinetic assumptions are reasonable.
- Use within an approved therapeutic-drug-monitoring or medicines-governance pathway.
- Use to support transparent review, not to automate prescribing.
How It Is Calculated
- C(reference) = C(measured) × e^[k × (sample time − reference time)].
- MedicalC validates that all required inputs are numeric and rejects internally impossible time or concentration relationships where applicable.
Interpretation
- This is a model-based Gentamicin concentration at the selected post-infusion reference time. Compare only with a target defined at the same reference time.
- Interpret the result with the clinical indication, microbiology or seizure control, organ function, assay timing and local targets.
Worked Example
Enter a verified set of source values in the displayed units. MedicalC applies: C(reference) = C(measured) × e^[k × (sample time − reference time)]. Recheck the source chart and sampling times before using the result.
Patient Considerations
- Primarily intended for clinically stable adults receiving intermittent intravenous aminoglycoside therapy. Paediatric, neonatal, pregnancy, obesity, burns, cystic fibrosis, dialysis and rapidly changing renal function require specialist protocols.
- Consider acute kidney injury, augmented renal clearance, fluid shifts, obesity, burns, pregnancy, critical illness and interacting medicines.
Limitations
- One-compartment equations may not describe distribution or multicompartment behaviour accurately.
- Derived values can appear precise despite uncertainty in sampling time, assay result and clearance stability.
- A calculated exposure or dose does not establish clinical benefit or safety.
Clinical Pearls
- A target such as a protocol-defined post-distribution peak is meaningful only when the local protocol specifies the same sampling or extrapolation convention.
- Plot concentrations against actual elapsed time before accepting any pharmacokinetic slope.
- When the result conflicts with the patient, verify the data rather than forcing a dose change.
Common Mistakes
- Using scheduled rather than actual administration and blood-sampling times.
- Treating a level drawn during distribution as a post-distribution concentration.
- Mixing mg/L, micrograms/mL and micrograms/L.
- Applying steady-state equations before steady state or during changing clearance.
- Using a generic concentration target outside the relevant indication or local protocol.
Evidence Base
Principal source: Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. McGraw-Hill; 2015.
Frequently Asked Questions
What does the Gentamicin Extrapolated Post-Distribution Peak calculator estimate?
Back-extrapolates a measured post-distribution Gentamicin concentration to a selected peak reference time.
Can this result be used to prescribe automatically?
No. It requires clinician and pharmacist interpretation within a drug-specific protocol.
Why do actual administration and sample times matter?
Small timing errors can materially change an elimination slope, projected concentration or calculated exposure.
What should be checked after using the result?
Recheck serum creatinine, urine output, dosing and sampling times, concomitant nephrotoxins and repeat drug levels according to the local aminoglycoside protocol. Review urgently if renal function changes or ototoxicity/nephrotoxicity is suspected.
When is a direct or Bayesian method preferable?
Use a validated Bayesian platform or direct free-level measurement when recommended, especially in complex or unstable patients.
References
- Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. McGraw-Hill; 2015. — Primary publication, consensus guideline or authoritative pharmacokinetic source.
Reviewed by: MedicalC Clinical Editorial Team
Last reviewed: July 2026
